Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). , Clin Infect Dis: 2024
Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR. Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine. , Clin Infect Dis: 2024
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. , N Engl J Med: 2024
apasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ. Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon- , J Immunol.: 2024
Livio Azzoni, Ian Tietjen, Qin Liu, Shalini Singh, Mansi Purwar, Matthew Fair, Paridhima Sharma, Leila B. Giron, Jianyi Ding, Linden Lalley-Chareczko, Emily Hiserodt, Karam Mounzer, David B. Weiner, Mohamed Abdel-Mohsen, Luis J. Montaner Prior COVID-19 Alters Antibody Function in ART-Suppressed PWH Receiving SARS-CoV-2 Vaccination , CROI: 2024
Francesco E. Marino, Maxime Bellefroid, Ryan Krause, Marie Armani-Tourret, Suvadip Mallick, Emmanouil Papasavvas, Matthew Fair, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Mathias Lichterfeld, Katharine J. Bar Autologous Neutralizing Antibodies Contribute to Virus Control in a Subset of PWH Treated With bNAbs , CROI: 2024
Anthony M. Mills, MD, Laurence Brunet, PhD, Kevin R. Frost, BM, Gerald Pierone, MD, Jr., Michael G. Sension, MD, Philip C. Lackey, MD, Karam Mounzer, MD:, Michael B. Wohlfeiler, JD, MD, , Jennifer S. Fusco, BS:, Carolyn A. Brown, MSPH, PhD: ViiV Healthcare/GSK: Stocks/Bonds (Public Company), Vani Vannappagari, MBBS, MPH, PhD:, Michael Aboud, MBChB, MRCP:, Piotr Budnik, MBBCh FCP(SA):, Gregory P. Fusco, MD, MPH Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort , ID WEEK : 2024
EMMANOUIL PAPASAVVAS, Jessicamarie Morris, Brian N. Ross, Matthew Fair, Livio Azzoni, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Luis J. Montaner Lower ADCC After 26 Weeks of PEG-IFN-α2b and 2 bNAbs in Otherwise Suppressed HIV-1+ , CROI: 2024
Anthony Mills, Laurence Brunet, Karam Mounzer, Michael B. Wohlfeiler, Kevin R. Frost, Ricky K. Hsu, Gerald Pierone, Michael Sension, Philip C. Lackey, Jennifer S. Fusco, Carolyn Brown, Vani Vannappagari, Michael Aboud, Piotr Budnik, Gregory P. Fusco Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort , CROI: 2024
Karam Mounzer, Laurence Brunet, Michael Sension, Ricky K. Hsu, Jennifer S. Fusco, Yohance O. Whiteside, Gregory P. Fusco Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US , CROI: 2024
